anti-CD19 CAR T-cell therapy (Beijing Winwin Kechuang Biotechnology/Kecellitics Biotech Company)

N/A

Report date: 2025/01/26 16:53:30

Base Information

Drug Nameanti-CD19 CAR T-cell therapy (Beijing Winwin Kechuang Biotechnology/Kecellitics Biotech Company)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, B-CellLymphoma, Non-Hodgkin +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijing Win Win Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Win Win Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLymphoma, B-CellLymphoma, Non-Hodgkin +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A